Publications & Posters
Scholarly publications
Spinal Muscular Atrophy
Apitegromab
October 2025
World Muscle Society Annual Congress
Efficacy and safety of apitegromab in patients aged 13-21 years with Type 2 or 3 spinal muscular atrophy: outcomes from the SAPPHIRE Phase 3 trial (poster)
Spinal Muscular Atrophy
Apitegromab
September 2025
Neuromuscular Study Group Annual Scientific Meeting
Characterization of the longer-term effectiveness of SMN-targeted treatments for spinal muscular atrophy: A systematic literature review
Spinal Muscular Atrophy
Apitegromab
September 2025
Neuromuscular Study Group Annual Scientific Meeting
Efficacy and safety of apitegromab in individuals with type 2 and type 3 spinal muscular atrophy evaluated in the phase 3 SAPPHIRE trial
Spinal Muscular Atrophy
Apitegromab
August 2025
SMA Europe Clinical Care Symposium
Efficacy and safety of apitegromab in individuals with type 2 and type 3 spinal muscular atrophy evaluated in the phase 3 SAPPHIRE trial
Spinal Muscular Atrophy
Apitegromab
August 2025
Hawaii Pacific Neuroscience Symposium
Efficacy and safety of apitegromab in individuals with type 2 and type 3 spinal muscular atrophy evaluated in the phase 3 SAPPHIRE trial
Spinal Muscular Atrophy
Apitegromab
August 2025
SMA Europe Clinical Care Symposium
